189 related articles for article (PubMed ID: 28363584)
1. Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention.
Lavie CJ; Howden CW; Scheiman J; Tursi J
Curr Probl Cardiol; 2017 May; 42(5):146-164. PubMed ID: 28363584
[TBL] [Abstract][Full Text] [Related]
2. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care.
Martín Merino E; Johansson S; Nagy P; García Rodríguez LA
Am J Cardiol; 2013 Oct; 112(8):1075-82. PubMed ID: 23831164
[TBL] [Abstract][Full Text] [Related]
3. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
[TBL] [Abstract][Full Text] [Related]
4. Strategies to reduce the GI risks of antiplatelet therapy.
Scheiman JM
Rev Cardiovasc Med; 2005; 6 Suppl 4():S23-31. PubMed ID: 17710073
[TBL] [Abstract][Full Text] [Related]
5. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
Scheiman JM; Herlitz J; Veldhuyzen van Zanten SJ; Lanas A; Agewall S; Nauclér EC; Svedberg LE; Nagy P
J Cardiovasc Pharmacol; 2013 Mar; 61(3):250-7. PubMed ID: 23188121
[TBL] [Abstract][Full Text] [Related]
6. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment.
Lanas A; Scheiman J
Curr Med Res Opin; 2007 Jan; 23(1):163-73. PubMed ID: 17257477
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin.
Hsu PI; Tsai TJ
Curr Pharm Des; 2015; 21(35):5049-55. PubMed ID: 26369688
[TBL] [Abstract][Full Text] [Related]
8. Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events.
Sylvester KW; Cheng JW; Mehra MR
Vasc Health Risk Manag; 2013; 9():245-54. PubMed ID: 23696706
[TBL] [Abstract][Full Text] [Related]
9. Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance.
Kimmey MB
Am J Med; 2004 Sep; 117 Suppl 5A():72S-78S. PubMed ID: 15478856
[TBL] [Abstract][Full Text] [Related]
10. New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.
Hsu PI
J Gastroenterol Hepatol; 2012 Apr; 27(4):654-61. PubMed ID: 22283743
[TBL] [Abstract][Full Text] [Related]
11. The aspirin cardiovascular/gastrointestinal risk calculator--a tool to aid clinicians in practice.
Lanas A; Polo-Tomás M; Casado-Arroyo R
Aliment Pharmacol Ther; 2013 Apr; 37(7):738-48. PubMed ID: 23413984
[TBL] [Abstract][Full Text] [Related]
12. [Risk and prevention of gastrointestinal complications due to low-dose aspirin and other antiplatelet agents].
Bretagne JF
Rev Prat; 2008 Sep; 58(13):1434-6, 1439-40. PubMed ID: 18924327
[TBL] [Abstract][Full Text] [Related]
13. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.
Sharma T; Bliden K; Chaudhary R; Tantry U; Gurbel PA
Expert Opin Pharmacother; 2017 Jan; 18(1):123-131. PubMed ID: 27937054
[TBL] [Abstract][Full Text] [Related]
15. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
Peura DA; Wilcox CM
Postgrad Med; 2014 Jan; 126(1):87-96. PubMed ID: 24393755
[TBL] [Abstract][Full Text] [Related]
16. Management of patients with high gastrointestinal risk on antiplatelet therapy.
Cryer B
Gastroenterol Clin North Am; 2009 Jun; 38(2):289-303. PubMed ID: 19446259
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries.
Mo C; Sun G; Lu ML; Zhang L; Wang YZ; Sun X; Yang YS
World J Gastroenterol; 2015 May; 21(17):5382-92. PubMed ID: 25954113
[TBL] [Abstract][Full Text] [Related]
18. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy.
Casado Arroyo R; Polo-Tomas M; Roncalés MP; Scheiman J; Lanas A
Heart; 2012 May; 98(9):718-23. PubMed ID: 22523056
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk.
Goldstein JL; Whellan DJ; Scheiman JM; Cryer BL; Eisen GM; Lanas A; Fort JG
Cardiovasc Ther; 2016 Apr; 34(2):59-66. PubMed ID: 26725920
[TBL] [Abstract][Full Text] [Related]
20. Aspirin in cardiology--benefits and risks.
Björklund L; Wallander MA; Johansson S; Lesén E
Int J Clin Pract; 2009 Mar; 63(3):468-77. PubMed ID: 19222632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
